Sugi Predict

Sugi Predict / Compounds / SCHEMBL8140909

SCHEMBL8140909

SCHEMBL8140909

COC(=O)C1CCN(CC(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ TP53 P04637 1/20 0.45
▸ GAA P10253 1/20 0.43
▸ WNT1 P04628 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ DYRK1A Q13627 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTR4 Q13639 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873641 0.91 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2TP53GAAWNT1
SCHEMBL2471930 0.91 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2TP53GAAWNT1
SCHEMBL27365079 0.85 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2TP53GAAMEN1
SCHEMBL5701048 0.85 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL26891587 0.84 WNT1 (0.42) ALDH1A1SMN1; SMN2WNT1GSK3BDYRK1A
SCHEMBL5701008 0.84 HSD17B10 (0.46) SMN1; SMN2WNT1GSK3BDYRK1AKMT2A
SCHEMBL23542428 0.83 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2TP53GAAMEN1
SCHEMBL8486056 0.83 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2GAAWNT1GSK3B
SCHEMBL9281583 0.83 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2TP53GAAMEN1
SCHEMBL7377754 0.81 WNT1 (0.41) ALDH1A1SMN1; SMN2GAAWNT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
US-12415796-B2 Inhibitors of (αv)(β6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-09-16 — — US disclosed
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2024-10-03 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
CN-116283977-A Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-06-23 — — CN disclosed
CN-110573499-B Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-04-21 — — CN disclosed
EP-4159727-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2023-04-05 — — EP disclosed
CN-115677824-A Compound capable of inducing degradation of SOS1 protein, preparation method and application 中国科学院上海药物研究所 2023-02-03 — — CN disclosed
US-9181266-B2 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors NOVARTIS AG (CH) 2015-11-10 — — US disclosed
EP-2731942-B1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-09-23 — — EP disclosed
EP-2731942-B1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-09-23 — — EP disclosed
US-20150025070-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-01-22 — — US disclosed
US-20150025070-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-01-22 — — US disclosed
US-20150025070-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-01-22 — — US disclosed
EP-2731942-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS Novartis AG (CH) 2014-05-21 — — EP disclosed
WO-2013012723-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2013-01-24 — — WO disclosed
WO-2013012723-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2013-01-24 — — WO disclosed
US-6069143-A Fibrinogen receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2000-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ALDH1A1 1534/4885SMN1; SMN2 2648/4885TP53 2842/4885
US-12415796-B2 Inhibitors of (αv)(β6) integrin ITGB6, ITGA6, ITGAV ALDH1A1 2417/4885SMN1; SMN2 2499/4885TP53 3112/4885
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ALDH1A1 1727/4885SMN1; SMN2 2731/4885TP53 2941/4885
US-20150025070-A1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS WNT1, TNKS1BP1, TNKS ALDH1A1 410/4885SMN1; SMN2 4058/4885TP53 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.